{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T22:01:38Z","timestamp":1769724098412,"version":"3.49.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.clgc.2016.05.012","type":"journal-article","created":{"date-parts":[[2016,5,28]],"date-time":"2016-05-28T21:00:19Z","timestamp":1464469219000},"page":"176-181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Development of a Nomogram for Predicting Severe Neutropenia Associated With Docetaxel-Based Chemotherapy in Patients With Castration-Resistant Prostate Cancer"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1563-4888","authenticated-orcid":false,"given":"Yosuke","family":"Hirasawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Sugihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Issei","family":"Takizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuo","family":"Gondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Nakagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Horiguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Namiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Ohori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2016.05.012_bib1","first-page":"69","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2016.05.012_bib2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2165\/10898600-000000000-00000","article-title":"Castration-resistant prostate cancer: current and emerging treatment strategies","volume":"70","author":"Di Lorenzo","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.clgc.2016.05.012_bib3","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.05.012_bib4","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.05.012_bib5","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2016.05.012_bib6","unstructured":"American Urological Association. Guidelines: Castration-Resistant Prostate Cancer. Available at: http:\/\/www.auanet.org\/education\/guidelines\/castration-resistant-prostate-cancer.cfm."},{"key":"10.1016\/j.clgc.2016.05.012_bib7","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.05.012_bib8","unstructured":"National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Available at: http:\/\/evsncinihgov\/ftp1\/CTCAE\/CTCAE_403_2010-06-14_QuickReference_5x7pdf."},{"key":"10.1016\/j.clgc.2016.05.012_bib9","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jjco\/hyn029","article-title":"Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan","volume":"38","author":"Naito","year":"2008","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.clgc.2016.05.012_bib10","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/sj.bjc.6600768","article-title":"Metastatic renal carcinoma comprehensive prognostic system","volume":"88","author":"Atzpodien","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2016.05.012_bib11","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.urology.2014.05.041","article-title":"Prediction of multifocal lesions in patients with upper tract urothelial carcinoma","volume":"84","author":"Hashimoto","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2016.05.012_bib12","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/nrclinonc.2014.71","article-title":"Challenges of managing elderly men with prostate cancer","volume":"11","author":"Jha","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"issue":"4 suppl 2","key":"10.1016\/j.clgc.2016.05.012_bib13","first-page":"18","article-title":"Greater risks of chemotherapy toxicity in elderly patients with cancer","volume":"1","author":"Repetto","year":"2003","journal-title":"J\u00a0Support Oncol"},{"key":"10.1016\/j.clgc.2016.05.012_bib14","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s10147-005-0490-0","article-title":"Treatment of androgen-independent, hormone-refractory prostate cancer with docetaxel in Japanese patients","volume":"10","author":"Miyoshi","year":"2005","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.clgc.2016.05.012_bib15","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/sj.bjc.6690375","article-title":"Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Cooperative Group of Docetaxel for Pancreatic Cancer in Japan","volume":"80","author":"Okada","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2016.05.012_bib16","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1002\/cncr.20983","article-title":"Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy","volume":"103","author":"Caggiano","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2016.05.012_bib17","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.21847","article-title":"Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients","volume":"106","author":"Kuderer","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2016.05.012_bib18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.clgc.2012.06.004","article-title":"Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer","volume":"10","author":"Pond","year":"2012","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2016.05.012_bib19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejca.2015.12.009","article-title":"Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): a post-hoc analysis of the TROPIC phase III trial","volume":"56","author":"Meisel","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2016.05.012_bib20","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.7314\/APJCP.2014.15.8.3443","article-title":"Predictive factors for neutropenia after docetaxel-based systemic chemotherapy in Korean patients with castration- resistant prostate cancer","volume":"15","author":"Kwon","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.clgc.2016.05.012_bib21","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s10147-014-0746-7","article-title":"Predictive factors for severe and febrile neutropenia during docetaxel chemotherapy for castration-resistant prostate cancer","volume":"20","author":"Shigeta","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.clgc.2016.05.012_bib22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3816\/CLM.2001.n.011","article-title":"The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin lymphoma receiving initial CHOP chemotherapy: a risk factor analysis","volume":"2","author":"Morrison","year":"2001","journal-title":"Clin Lymphoma"},{"key":"10.1016\/j.clgc.2016.05.012_bib23","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1200\/JCO.1997.15.8.2945","article-title":"Elderly patients with aggressive non-Hodgkin lymphoma: disease presentation, response to treatment, and survival\u2013a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years","volume":"15","author":"Bastion","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.05.012_bib24","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/oxfordjournals.annonc.a058727","article-title":"P-VEBEC: a new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin lymphoma (NHL)","volume":"5","author":"Bertini","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2016.05.012_bib25","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1200\/JCO.1998.16.7.2352","article-title":"Elderly patients with aggressive non-Hodgkin lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity","volume":"16","author":"Gomez","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.05.012_bib26","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1200\/JCO.1993.11.11.2250","article-title":"In search of an optimal regimen for elderly patients with advanced-stage diffuse large-cell lymphoma: results of a phase II study of P\/DOCE chemotherapy","volume":"11","author":"O'Reilly","year":"1993","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.05.012_bib27","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.1995.13.10.2530","article-title":"Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin lymphoma using CHOP versus CNOP chemotherapy","volume":"13","author":"Sonneveld","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.05.012_bib28","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1200\/JCO.1988.6.11.1708","article-title":"Non-Hodgkin lymphomas in 137 patients aged 70 years or older: a retrospective European Organization for Research and\u00a0Treatment of Cancer Lymphoma Group Study","volume":"6","author":"Tirelli","year":"1988","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.05.012_bib29","first-page":"33","article-title":"Elderly aggressive-histology non-Hodgkin lymphoma: first-line VNCOP-B regimen experience on 350 patients","volume":"94","author":"Zinzani","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.clgc.2016.05.012_bib30","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.ejca.2014.01.006","article-title":"Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme","volume":"50","author":"Heidenreich","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2016.05.012_bib31","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJMoa1000678","article-title":"Early palliative care for patients with metastatic non\u2013small-cell lung cancer","volume":"363","author":"Temel","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.clgc.2016.05.012_bib32","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1634\/theoncologist.2012-S1-23","article-title":"The importance of supportive care in optimizing treatment outcomes of patients with advanced prostate cancer","volume":"17","author":"Scotte","year":"2012","journal-title":"Oncologist"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767316301380?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767316301380?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:25:31Z","timestamp":1761564331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767316301380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S1558767316301380"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2016.05.012","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a Nomogram for Predicting Severe Neutropenia Associated With Docetaxel-Based Chemotherapy in Patients With Castration-Resistant Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2016.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}